Stocktoria
Allogene Therapeutics, Inc. ALLO
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-10-11
Allogene Therapeutics, Inc. institutional holders
| Investor | Shares | Value | % of company |
|---|---|---|---|
| BlackRock Finance, Inc. | 16,445,682 | $38.3M | 7.17% |
| CITADEL ADVISORS LLC | 6,887,120 | $16.8M | 3% |
| TWO SIGMA INVESTMENTS, LP | 5,375,456 | $13.1M | 2.34% |
| MILLENNIUM MANAGEMENT LLC | 3,322,053 | $8.1M | 1.45% |
| D. E. Shaw & Co., Inc. | 2,763,776 | $6.7M | 1.2% |
| AQR CAPITAL MANAGEMENT LLC | 2,484,780 | $6.1M | 1.08% |
| RENAISSANCE TECHNOLOGIES LLC | 2,139,328 | $5.2M | 0.93% |
| Point72 Asset Management, L.P. | 221,335 | $540,057 | 0.1% |
% of company = reported institutional shares ÷ shares outstanding. Based on the latest reports; not every holder reports every quarter.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.